The Lundquist Institute

Running trials

• Recruiting

  A Study to Evaluate Different Targeted Therapies for Patients With Rheumatoid Arthritis

  NCT06972446· Phase 2· AbbVie· Source

• Active, not recruiting

  Cadisegliatin as Adjunctive Therapy to Insulin in Participants With Type 1 Diabetes

  NCT06334133· Phase 3· vTv Therapeutics· Source

• Active, not recruiting

  A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006)

  NCT06079879· Phase 3· Merck Sharp & Dohme LLC· Source

• Active, not recruiting

  Pulmonary Embolism - Thrombus Removal With Catheter-Directed Therapy

  NCT05591118· Phase 3· NYU Langone Health· Source

• Active, not recruiting

  Project 1: Diet and Exercise Modulate the Sperm Epigenome in Men

  NCT04175678· Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center· Source

• Active, not recruiting

  Examining the Genetic Factors That May Cause Chronic Obstructive Pulmonary Disease (COPD)

  NCT00608764· Brigham and Women's Hospital· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Rheumatoid arthritis1 recruiting

Closed trials

• Completed

  A Study to Test Asundexian for Preventing a Stroke Caused by a Clot in Participants After an Acute Ischemic Stroke or After a High-risk Transient Ischemic Attack, a So-called Mini Stroke

  NCT05686070· Phase 3· Bayer· Source

• Completed

  A Study Testing the Use of a Perivascular Sirolimus Formulation (Sirogen) in ESRD Patients Undergoing AV Fistula Surgery

  NCT05425056· Phase 3· Vascular Therapies, Inc.· Source

• Completed

  A Study of Tirzepatide (LY3298176) in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF) and Obesity: The SUMMIT Trial

  NCT04847557· Phase 3· Eli Lilly and Company· Source

• Completed

  Study to Evaluate the Efficacy (Effect on Disease) and Safety of Finerenone in Participants With Heart Failure and Left Ventricular Ejection Fraction (Proportion of Blood Expelled Per Heart Stroke) Greater or Equal to 40%

  NCT04435626· Phase 3· Bayer· Source

• Completed

  Randomized, Double-Blind, Safety and Efficacy Study of RE-021 (Sparsentan) in Focal Segmental Glomerulosclerosis

  NCT01613118· Phase 2· Travere Therapeutics, Inc.· Source

Conditions

Diseases this institution publishes on or runs trials for.

• Coronary artery disease33 works · 0 trials
• COPD24 works · 1 trial
• Down syndrome9 works · 0 trials
• Neuromyelitis optica (NMOSD)5 works · 0 trials